- Home
- CRDO vs TAK Comparison
CRDO vs TAK Comparison
Compare CRDO & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRDO | TAK |
|---|---|---|
| Founded | 2008 | 1781 |
| Country | Cayman Islands | Japan |
| Employees | N/A | 47455 |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.8B | 52.4B |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | CRDO | TAK |
|---|---|---|
| Price | $251.04 | $15.97 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 14 | 0 |
| Target Price | ★ $179.62 | N/A |
| AVG Volume (30 Days) | ★ 8.3M | 3.0M |
| Earning Date | 06-01-2026 | 05-13-2026 |
| Dividend Yield | N/A | ★ 3.24% |
| EPS Growth | ★ 261.11 | N/A |
| EPS | ★ 1.62 | N/A |
| Revenue | ★ $436,775,000.00 | N/A |
| Revenue This Year | $210.92 | $0.16 |
| Revenue Next Year | $57.22 | $1.22 |
| P/E Ratio | $163.45 | ★ $41.25 |
| Revenue Growth | ★ 126.34 | N/A |
| 52 Week Low | $75.61 | $12.99 |
| 52 Week High | $268.18 | $18.90 |
Technical Indicators
Market Signals| Indicator | CRDO | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 64.79 | 47.73 |
| Support Level | $132.85 | $15.63 |
| Resistance Level | N/A | $16.48 |
| Average True Range (ATR) | 26.18 | 0.21 |
| MACD | 2.34 | 0.07 |
| Stochastic Oscillator | 74.06 | 79.72 |
Price Performance
Historical ComparisonAbout CRDO Credo Technology Group Holding Ltd
Credo Technology Group Holding Ltd delivers high-speed solutions to break bandwidth barriers on every wired connection in the data infrastructure market. It provides secure, high-speed connectivity solutions that deliver improved power and cost efficiency as data rates and corresponding bandwidth requirements increase exponentially throughout the data infrastructure market. It has a geographic presence in Hong Kong, the United States, Mainland China, Taiwan, and the Rest of the World.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.